• Publications
  • Influence
MEK and the inhibitors: from bench to bedside
TLDR
This review summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162, RO5126766, WX-554, RO4987655, GDC-0973 (XL518), and AZD8330, and summarized new MAP kinase signaling pathways involving 7 MEK enzymes. Expand
Ibrutinib and novel BTK inhibitors in clinical development
TLDR
Ibrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical effectiveness and tolerability in early clinical trials and has progressed into phase III trials, but additional research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition. Expand
Novel CD20 monoclonal antibodies for lymphoma therapy
TLDR
This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumAB (PRO70769), and third-generationmAbs, AME-133v (ocaratuzumAB), PRO131921 and GA101 (obinutumumab). Expand
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
TLDR
Early data on selective JAK inhibitors, including SAR302503 (TG101348), lestaurtinib (CEP701), CYT387, SB1518 (pacritinib), LY2784544, XL019, BMS-911543, NS-018, and AZD1480 are summarized. Expand
STAT inhibitors for cancer therapy
TLDR
This review summarized advances in preclinical and clinical development of inhibitors targeting STAT3 and STAT5, including peptidomimetics, small molecule inhibitors and oligonucleotides. Expand
To stage or not to stage
MP3: ROLE OF HISTONE DEACTYLASE (HDAC) INHIBITORS IN ADULT T-CELL LYMPHOMA/LEUKEMIA (ATL)
TLDR
In the small experience of romidepsin in relapsed/refractory ATL, patients appear to have modest response rates and higher rate of cytopenias when compared to other PTCL subtypes in clinical trials. Expand
Current management and novel agents for malignant melanoma
TLDR
This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy. Expand
Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy
TLDR
Two patients with active MM with relapsed ISS III B kappa light chain myeloma are presented in whom persistent chalazia became a therapy-interfering complication of treatment with bortezomib. Expand
...
1
2
3
...